DT
The startup is developing a high-dose oral statin specifically for patients in the intermediate stage of age-related macular degeneration (AMD), a condition with limited treatment options that can lead to late-stage blindness. This therapeutic approach aims to significantly slow the progression of the disease, providing a critical intervention for at-risk patients.
Updated 3 months ago
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is developing a high-dose oral statin specifically for patients in the intermediate stage of age-related macular degeneration (AMD), a condition with limited treatment options that can lead to late-stage blindness. This therapeutic approach aims to significantly slow the progression of the disease, providing a critical intervention for at-risk patients.